<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780609</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18630</org_study_id>
    <nct_id>NCT02780609</nct_id>
  </id_info>
  <brief_title>Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma</brief_title>
  <official_title>Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I: The primary purpose of this study phase is to determine the best dose also referred
      to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose
      melphalan as a conditioning regimen for hematopoietic cell transplant.

      Phase II: The primary purpose of this study phase is to assess the complete response (CR)
      conversion rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Recommended Phase II Dose (RPh2D)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>RPh2D/Maximum Tolerated Dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. MTD: the highest dose level at which 1 or less of 6 participants experience a dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Complete Response (CR)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>Complete response (CR) conversion rate. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.
tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.
Complete Response conversion rate. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>Progressive Disease (PD) as outlined by International Myeloma Working Group (IMWG) uniform response criteria by response subcategory for multiple myeloma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>Rate of participants' survival at time of evaluation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Minimal Residual Disease (MRD)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>To assess minimal residual disease (MRD) with PET scan, bone marrow flow cytometry and/or immunoglobulin gene sequencing at 3 months after autologous HCT (exploratory endpoint).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 100 mg/m^2 IV over 30-45 minutes.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Cell Transplantation (HCT)</intervention_name>
    <description>Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <description>Fosaprepitant at 150 mg IV on days -3 and -2.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>antiemetic agent</other_name>
    <other_name>Standare of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older with histologically confirmed multiple myeloma

          -  Achieving partial response (PR) or very good partial response (VGPR) with systemic
             chemotherapy

          -  Received less than 4 lines of anti-myeloma therapy.

          -  Karnofsky performance status of &gt;= 70%

          -  Adequate pulmonary, cardiac, hepatic and renal function as outlined in the protocol

          -  Signed informed consent form in accordance with institutional policies prior to the
             initiation of high-dose therapy

        Exclusion Criteria:

          -  Non-secretory multiple myeloma

          -  Have achieved complete response (CR) prior to autologous hematopoietic cell
             transplantation (HCT)

          -  Central nervous system (CNS) involvement

          -  Uncontrolled bacterial, viral or fungal infections

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

          -  Prior malignancies within the last 5 years except resected basal cell carcinoma or
             treated cervical carcinoma in situ.

          -  Females who are pregnant or breastfeeding

          -  Have received other investigational drugs within 14 days prior to screening

          -  Prior autologous or allogeneic HCT

          -  Prior organ transplant or autoimmune disease requiring immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiga Nishihori, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlyn Ward</last_name>
      <phone>813-745-8986</phone>
      <email>caitlyn.ward@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Taiga Nishihori, M.D.</last_name>
      <phone>813-745-8156</phone>
      <email>taiga.nishihori@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Taiga Nishihori, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Sullivan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Alsina, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachid Baz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose L. Ochoa-Bayona, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Shain, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Turner, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous hematopoietic cell transplantation (HCT)</keyword>
  <keyword>high-dose melphalan</keyword>
  <keyword>selinexor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

